Quark Pharmaceuticals announced today the publication of data showing that one of its proprietary gene targets, RTP801, plays a role in cigarette smoke-induced pulmonary injury and emphysema.

In a paper published in Nature Medicine, researchers reported "increased levels of RTP801 mRNA and protein in the lungs of humans suffering from emphysema and in the lungs of mice exposed to cigarette smoke," Quark said. "Unlike normal mice, mice that could not express RTP801 did not develop emphysema following six months of intensive exposure to cigarette smoke."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.